PRAX Insider Jill Desimone Buys $826K of Stock

Jill Desimone, an insider at Praxis Precision Medicines, Inc., made a notable purchase on June 24, 2026. She bought 11,600 shares of the company at an average price of $71.20 per share, totaling roughly $825,953.64. This transaction was not part of a pre-planned trading program, indicating a direct decision to acquire the shares.

Insider Buying and Selling at Praxis Precision Medicines, Inc.

On June 24, 2026, Jill Desimone acquired 11,600 shares of Praxis Precision Medicines at an average price of $71.20 per share, amounting to $825,953.64. This transaction was not under a Rule 10b5-1 plan, suggesting it was a discretionary purchase. Earlier in June, on the 10th, Desimone also bought 648 shares, while Dean Mitchell purchased 1,371 shares, and Stuart Arbuckle bought 648 shares, all without pre-planned trading plans.

Praxis Precision Medicines, Inc. Stock Up 9.6%

Shares of NasdaqGS:PRAX traded near $327.79 on Saturday. Praxis Precision Medicines, Inc. has a market capitalization of approximately $9.14 billion. The stock has experienced significant volatility, with a 52-week range between $37.19 and $366.52. Its 50-day moving average stands at $314.76, while the 200-day moving average is $252.07. The company exhibits a high beta of 2.749, indicating higher volatility compared to the market.

Analysts Set New Price Targets

On June 18, 2026, RBC Capital initiated coverage on Praxis Precision Medicines with a buy rating and set a price target of $449. Earlier in June, Oppenheimer, Truist Securities, Deutsche Bank, and Baird maintained their buy ratings with targets of $650, $616, $374, and $400 respectively. Meanwhile, Wedbush maintained a sell rating with a target of $162. The consensus among analysts is strong buy, with a mean target price of $617.67 based on 18 analyst opinions.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. It focuses on developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include Cerebrum for CNS small molecule therapies and Solidus for antisense oligonucleotide development. Praxis is advancing several candidates, including ulixacaltamide and relutrigine, in various stages of clinical trials. Founded in 2015, the company is led by CEO Marcio Silva De'Souza and employs 168 people.

Bottom Line

Jill Desimone's recent purchase of Praxis Precision Medicines shares underscores her confidence in the company's prospects. With a robust pipeline targeting neurological disorders, the company remains a point of interest for investors. Analysts have shown strong support, as evidenced by recent buy ratings and price targets. As always, it's important to remember that insider transactions and analyst ratings are just parts of the broader investment landscape.